Phillip Huyett1. 1. Division of Sleep Medicine and Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.
Abstract
STUDY OBJECTIVES: To assess early adherence to therapy with hypoglossal nerve stimulation therapy. METHODS: This is a prospective study of consecutive patients with moderate to severe obstructive sleep apnea who underwent implantation of hypoglossal nerve stimulation therapy within a single academic practice and attended a follow-up appointment after greater than 30 days of therapy use. Objective adherence data were extracted from an objective monitoring database and compared to patient characteristics. RESULTS: The study population was 79 participants who were 29.1% female with a mean age of 58.7 ± 12.8 years old, body mass index of 28.9 ± 3.4 kg/m2, and baseline apnea-hypopnea index of 33.8 ± 17.6 events/h. In the first 7 days after device activation, average use was 7.8 h/night, with 91.9% of nights with greater than 4 hours of therapy use and an average of 0.2 pauses in therapy per night. These figures remained stable after 30 days of use: 7.7 h/night, 91.0% of nights longer than 4 hours, and 0.3 pauses per night. Objective evidence of difficulty with acclimatization was associated with age less than 60 years (odds ratio 2.8, 95% confidence interval 1.1-7.1, P = .03) and a history of prior upper airway surgery (3.9, 1.2-11.9, P = .015). Insomnia was present in 31 patients and was not associated with objective evidence of difficulty tolerating therapy. CONCLUSIONS: Early adherence to hypoglossal nerve stimulation is excellent (92.4% >4 hours on >70% of nights), suggesting that the acclimatization period is straightforward in most. Younger age and a history of prior upper airway surgery appear to be associated with an increased risk of difficulty with acclimatization. CITATION: Huyett P. Early objective adherence to hypoglossal nerve stimulation therapy. J Clin Sleep Med. 2022;18(2):631-636.
STUDY OBJECTIVES: To assess early adherence to therapy with hypoglossal nerve stimulation therapy. METHODS: This is a prospective study of consecutive patients with moderate to severe obstructive sleep apnea who underwent implantation of hypoglossal nerve stimulation therapy within a single academic practice and attended a follow-up appointment after greater than 30 days of therapy use. Objective adherence data were extracted from an objective monitoring database and compared to patient characteristics. RESULTS: The study population was 79 participants who were 29.1% female with a mean age of 58.7 ± 12.8 years old, body mass index of 28.9 ± 3.4 kg/m2, and baseline apnea-hypopnea index of 33.8 ± 17.6 events/h. In the first 7 days after device activation, average use was 7.8 h/night, with 91.9% of nights with greater than 4 hours of therapy use and an average of 0.2 pauses in therapy per night. These figures remained stable after 30 days of use: 7.7 h/night, 91.0% of nights longer than 4 hours, and 0.3 pauses per night. Objective evidence of difficulty with acclimatization was associated with age less than 60 years (odds ratio 2.8, 95% confidence interval 1.1-7.1, P = .03) and a history of prior upper airway surgery (3.9, 1.2-11.9, P = .015). Insomnia was present in 31 patients and was not associated with objective evidence of difficulty tolerating therapy. CONCLUSIONS: Early adherence to hypoglossal nerve stimulation is excellent (92.4% >4 hours on >70% of nights), suggesting that the acclimatization period is straightforward in most. Younger age and a history of prior upper airway surgery appear to be associated with an increased risk of difficulty with acclimatization. CITATION: Huyett P. Early objective adherence to hypoglossal nerve stimulation therapy. J Clin Sleep Med. 2022;18(2):631-636.
Authors: T E Weaver; N B Kribbs; A I Pack; L R Kline; D K Chugh; G Maislin; P L Smith; A R Schwartz; N M Schubert; K A Gillen; D F Dinges Journal: Sleep Date: 1997-04 Impact factor: 5.849
Authors: Susheel P Patil; Indu A Ayappa; Sean M Caples; R Joh Kimoff; Sanjay R Patel; Christopher G Harrod Journal: J Clin Sleep Med Date: 2019-02-15 Impact factor: 4.062
Authors: Scott A Sands; Philip I Terrill; Bradley A Edwards; Luigi Taranto Montemurro; Ali Azarbarzin; Melania Marques; Camila M de Melo; Stephen H Loring; James P Butler; David P White; Andrew Wellman Journal: Sleep Date: 2018-01-01 Impact factor: 5.849
Authors: Nurit Fox; A J Hirsch-Allen; Elizabeth Goodfellow; Joshua Wenner; John Fleetham; C Frank Ryan; Mila Kwiatkowska; Najib T Ayas Journal: Sleep Date: 2012-04-01 Impact factor: 5.849
Authors: Christopher J Lettieri; Anita A Shah; Aaron B Holley; William F Kelly; Audrey S Chang; Stuart A Roop Journal: Ann Intern Med Date: 2009-11-17 Impact factor: 25.391
Authors: Marijke Dieltjens; Marc J Braem; Anneclaire V M T Vroegop; Kristien Wouters; Johan A Verbraecken; Wilfried A De Backer; Paul H Van de Heyning; Olivier M Vanderveken Journal: Chest Date: 2013-11 Impact factor: 9.410
Authors: Faith S Luyster; Quan Ni; Kent Lee; Christine Harrison; Vaibhav H Ramprasad; Ryan J Soose; Patrick J Strollo Journal: J Clin Sleep Med Date: 2022-09-01 Impact factor: 4.324